Bristol Myers Squibb stock: Zacks lifts 2027 EPS estimate
Published on 11/16/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat The Estimate Change Signals
- Zacks Research raised its forecast for Bristol Myers Squibb's third-quarter 2027 earnings.
- The analyst retained a Hold rating despite the higher quarterly estimate.
- Investors continue to weigh earnings expectations against the company's long-term drug portfolio.
Zacks Research raised its forecast for Bristol Myers Squibb's third-quarter 2027 earnings per share to 1.74 US dollars from 1.55 in a research note issued on Wednesday, November 11, according to MarketBeat. Zacks maintained its Hold rating on the shares.
Higher Quarterly Estimate
The revision points to a stronger near-term earnings expectation from Zacks, but it does not amount to a broader rating change. MarketBeat said Zacks also issued estimates covering later reporting periods, while the current full-year consensus stood at 6.46 US dollars per share.
MarketBeat also reported that Bristol Myers Squibb delivered quarterly earnings of 1.35 US dollars per share against a 1.10 US dollar consensus estimate. Quarterly revenue reached 13.07 billion US dollars, compared with a 12.72 billion US dollar consensus and 6.9 percent growth from the prior-year quarter.
Mixed Signals For Investors
The updated estimate adds a positive revision to an otherwise cautious analyst picture. MarketBeat said its consensus rating for Bristol Myers Squibb remained Hold, with an average price target of 65.46 US dollars.
Bristol Myers Squibb stock traded at 57.96 euros on Lang & Schwarz at 15:37 CET on Monday, November 16, 2026. The quote gives investors a current European-market indication, while the analyst revision provides the more relevant new company-specific development.
Bristol Myers Squibb stock facts
- Company: Bristol Myers Squibb
- ISIN: US1101221083
- WKN: 850501
- Ticker: BMY
- Primary exchange: New York Stock Exchange
- Lang & Schwarz quote: 57.96 euros at 15:37 CET on November 16, 2026
US market conditions remain relevant for Bristol Myers Squibb investors; see Current market reports.
Further estimate revisions and company developments may shape the investment debate. See More news and analyses on Bristol Myers Squibb stock.
